Tower Research Capital LLC (Trc) Viracta Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $5.8 Billion
- Q2 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 12,652 shares of VIRX stock, worth $2,783. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,652
Previous 8,889
42.33%
Holding current value
$2,783
Previous $9,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding VIRX
# of Institutions
44Shares Held
9.03MCall Options Held
10.9KPut Options Held
400-
Bvf Inc San Francisco, CA3.61MShares$795,2250.06% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.52MShares$334,4520.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.16MShares$255,4810.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA690KShares$151,7350.19% of portfolio
-
Laurion Capital Management LP New York, NY407KShares$89,6050.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $8.26M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...